What can we conclude about the role of IV vitamin C after 33 years of trials involving at least 1,600 patients?
The Role of Vitamin C in the Treatment of Terminal Cancer
Studies in the 70’s showed an extraordinary survival gain in terminal cancer patients with vitamin C, a simple, relatively nontoxic therapy. So, no wonder it got a lot of attention, especially when reported by a world-renowned scientist, Linus Pauling. But studies like this in the 1980’s found no such benefit. So, alas, they were left with the inevitable conclusion that the apparent positive results in the original study were the product of bias rather than treatment effectiveness. In the 1990’s, though, an alternative explanation arose. The disappointing 80’s research only used oral vitamin C, whereas the apparently successful 70’s experiments also gave vitamin C intravenously, and we didn’t realize until the 90’s that the same dose given IV can lead to dramatically higher levels in the bloodstream than if taken orally. So, maybe high dose vitamin C does help in terminal cancer, but maybe only when given intravenously.
Encouraging case reports continued to be published. Here, there was a regression, remission, and cure documented in individual cases of advanced kidney cancer, bladder cancer, and lymphoma. But that was three success stories out of how many? If it was three out of a hundred, or even three out of a thousand, well ok, if the treatment is sufficiently nontoxic. But there’s evidence that IV vitamin C is widely used in the alternative medicine world, as in 86% of 172 practitioners surveyed. Just those 172 practitioners alone treated about 10,000 patients a year. And you ask the manufacturers, and they’re selling hundreds of thousands of vials of this stuff in the U.S. Now, it’s not all being used for cancer, but presumably at least thousands of cancer patients are being treated every year with IV vitamin C, making the publication of three remarkable case reports seem less impressive. So, no matter how amazing these cases seemed, it’s possible the cancers just spontaneously regressed all on their own, and it was just a coincidence that it happened after they were given vitamin C. To know for sure, you have to put it to the test.
To date, there have been some small pilot studies, and the results so far have been disappointing. The good news is that even insane doses of IV vitamin C seem remarkably safe, but failed, in this study of two dozen patients, to demonstrate anticancer activity. Similar small studies have been published, all the way through to the present with tantalizing but inconclusive results. What we do know is that the present state of cancer treatment is unsatisfactory. People have this perception that chemotherapy will significantly enhance their chances for a cure, but put all our cancer-killing chemo together and the overall contribution to 5-year survival is on the order of 2%. All those side-effects for 2.1%, at a cost of maybe $100,000 per patient per year. So, it may be worth looking deeper into therapies likes IV vitamin C. However, the lack of financial reward, since vitamin C can’t be patented and sold for $100,000, and bias against alternative medicine could dissuade conventional investigators and funding agencies from seriously considering this approach.
So, decades later what can we conclude? After trials which have included at least 1,600 patients over 33 years, we have to conclude that we still do not know whether vitamin C has any clinically significant antitumor activity. Although there is currently no definitive evidence of benefit, the Mayo Clinic randomized controlled trials do not negate the potential benefit based on what we now know about oral versus IV routes of administration. So, we’re kind of back at square one: does it work or not? There are highly polarized views on both sides, but everyone’s working off the same incomplete data. What we need are carefully controlled clinical trials. The question, though, is what do we do until then?
If it was completely nontoxic, then one could argue what have you got to lose, but it’s not; it’s only relatively nontoxic. For example, there have been rare but serious cases of kidney injury reported. After all, if it’s so safe, why did our bodies evolve to so tightly control against excess absorption? It can also be expensive and time-consuming. Each infusion can cost one to two hundred dollars out of pocket, which can be quite a boon for alternative medicine practitioners. About 90% of the millions of doses of vitamin C being dispensed are in for-profit arrangements; so, there’s financial pressures pushing in both directions.
Given the relative safety and expense, though, if controlled studies even find a small benefit, it would be worthwhile. And if they don’t, the vitamin C question can be put to rest once and for all, but in cancer treatment, we don’t have the luxury of jettisoning possibly effective relatively nontoxic treatments. We should revisit promising avenues, without prejudice, and with open minds.
To see any graphs, charts, graphics, images, and quotes to which Dr. Greger may be referring, watch the above video. This is just an approximation of the audio contributed by Katie Schloer.
Please consider volunteering to help out on the site.
- L J Hoffer, M Levine, S Assouline, D Melnychuk, S J Padayatty, K Rosadiuk, C Rousseau, L Robitaille, W H Miller Jr. Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. Ann Oncol. 2008 Nov;19(11):1969-74.
- H D Riordan, J J Casciari, M J González, N H Riordan, J R Miranda-Massari, P Taylor, J A Jackson. A pilot clinical study of continuous intravenous ascorbate in terminal cancer patients. P R Health Sci J. 2005 Dec;24(4):269-76.
- C M Stephenson, R D Levin, T Spector, C G Lis. Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer. Cancer Chemother Pharmacol. 2013 Jul;72(1):139-46.
- D A Monti, E Mitchell, A J Bazzan, S Littman, G Zabrecky, C J Yeo, M V Pillai, A B Newberg, S Deshmukh, M Levine. Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. PLoS One. 2012;7(1):e29794.
- F Cabanillas. Vitamin C and cancer: what can we conclude--1,609 patients and 33 years later? P R Health Sci J. 2010 Sep;29(3):215-7.
- C G Moertel, T R Fleming, E T Creagan, J Rubin, M J O'Connell, M M Ames. High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. N Engl J Med. 1985 Jan 17;312(3):137-41.
- C Jacobs, B Hutton, T Ng, R Shorr, M Clemons. Is there a role for oral or intravenous ascorbate (vitamin C) in treating patients with cancer? A systematic review. Oncologist. 2015 Feb;20(2):210-23.
- L N Cossey, F Rahim, C P Larsen. Oxalate nephropathy and intravenous vitamin C. Am J Kidney Dis. 2013 Jun;61(6):1032-5.
- S Ohno, Y Ohno, N Suzuki, G Soma, M Inoue. High-dose vitamin C (ascorbic acid) therapy in the treatment of patients with advanced cancer. Anticancer Res. 2009 Mar;29(3):809-15.
- S J Padayatty, H D Riordan, S M Hewitt, A Katz, L J Hoffer, M Levine. Intravenously administered vitamin C as cancer therapy: three cases.CMAJ. 2006 Mar 28;174(7):937-42.
- M Levine, S J Padayatty, M G Espey. Vitamin C: a concentration-function approach yields pharmacology and therapeutic discoveries. Adv Nutr. 2011 Mar;2(2):78-88.
- L J Hoffer, L Robitaille, R Zakarian, D Melnychuk, P Kavan, J Agulnik, V Cohen, D Small, W H Miller Jr. High-dose intravenous vitamin C combined with cytotoxic chemotherapy in patients with advanced cancer: a phase I-II clinical trial. PLoS One. 2015 Apr 7;10(4):e0120228.
- M K Wilson, B C Baguley, C Wall, M B Jameson, M P Findlay. Review of high-dose intravenous vitamin C as an anticancer agent. Asia Pac J Clin Oncol. 2014 Mar;10(1):22-37.
- G Morgan, R Ward, M Barton. The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies. Clin Oncol (R Coll Radiol). 2004 Dec;16(8):549-60.
- S Assouline, W H Miller. High-dose vitamin C therapy: renewed hope or false promise? CMAJ. 2006 Mar 28;174(7):956-7.
- S Mailankody, V Prasad. Comparative effectiveness questions in oncology. N Engl J Med. 2014 Apr 17;370(16):1478-81.
- S J Padayatty, A Y Sun, Q Chen, M G Espey, J Drisko, M Levine. Vitamin C: intravenous use by complementary and alternative medicine practitioners and adverse effects. PLoS One. 2010 Jul 7;5(7):e11414.
- J Blanchard, T N Tozer, M Rowland. Pharmacokinetic perspectives on megadoses of ascorbic acid. Am J Clin Nutr. 1997 Nov;66(5):1165-71.
Images thanks to Wendy via Flickr.
Studies in the 70’s showed an extraordinary survival gain in terminal cancer patients with vitamin C, a simple, relatively nontoxic therapy. So, no wonder it got a lot of attention, especially when reported by a world-renowned scientist, Linus Pauling. But studies like this in the 1980’s found no such benefit. So, alas, they were left with the inevitable conclusion that the apparent positive results in the original study were the product of bias rather than treatment effectiveness. In the 1990’s, though, an alternative explanation arose. The disappointing 80’s research only used oral vitamin C, whereas the apparently successful 70’s experiments also gave vitamin C intravenously, and we didn’t realize until the 90’s that the same dose given IV can lead to dramatically higher levels in the bloodstream than if taken orally. So, maybe high dose vitamin C does help in terminal cancer, but maybe only when given intravenously.
Encouraging case reports continued to be published. Here, there was a regression, remission, and cure documented in individual cases of advanced kidney cancer, bladder cancer, and lymphoma. But that was three success stories out of how many? If it was three out of a hundred, or even three out of a thousand, well ok, if the treatment is sufficiently nontoxic. But there’s evidence that IV vitamin C is widely used in the alternative medicine world, as in 86% of 172 practitioners surveyed. Just those 172 practitioners alone treated about 10,000 patients a year. And you ask the manufacturers, and they’re selling hundreds of thousands of vials of this stuff in the U.S. Now, it’s not all being used for cancer, but presumably at least thousands of cancer patients are being treated every year with IV vitamin C, making the publication of three remarkable case reports seem less impressive. So, no matter how amazing these cases seemed, it’s possible the cancers just spontaneously regressed all on their own, and it was just a coincidence that it happened after they were given vitamin C. To know for sure, you have to put it to the test.
To date, there have been some small pilot studies, and the results so far have been disappointing. The good news is that even insane doses of IV vitamin C seem remarkably safe, but failed, in this study of two dozen patients, to demonstrate anticancer activity. Similar small studies have been published, all the way through to the present with tantalizing but inconclusive results. What we do know is that the present state of cancer treatment is unsatisfactory. People have this perception that chemotherapy will significantly enhance their chances for a cure, but put all our cancer-killing chemo together and the overall contribution to 5-year survival is on the order of 2%. All those side-effects for 2.1%, at a cost of maybe $100,000 per patient per year. So, it may be worth looking deeper into therapies likes IV vitamin C. However, the lack of financial reward, since vitamin C can’t be patented and sold for $100,000, and bias against alternative medicine could dissuade conventional investigators and funding agencies from seriously considering this approach.
So, decades later what can we conclude? After trials which have included at least 1,600 patients over 33 years, we have to conclude that we still do not know whether vitamin C has any clinically significant antitumor activity. Although there is currently no definitive evidence of benefit, the Mayo Clinic randomized controlled trials do not negate the potential benefit based on what we now know about oral versus IV routes of administration. So, we’re kind of back at square one: does it work or not? There are highly polarized views on both sides, but everyone’s working off the same incomplete data. What we need are carefully controlled clinical trials. The question, though, is what do we do until then?
If it was completely nontoxic, then one could argue what have you got to lose, but it’s not; it’s only relatively nontoxic. For example, there have been rare but serious cases of kidney injury reported. After all, if it’s so safe, why did our bodies evolve to so tightly control against excess absorption? It can also be expensive and time-consuming. Each infusion can cost one to two hundred dollars out of pocket, which can be quite a boon for alternative medicine practitioners. About 90% of the millions of doses of vitamin C being dispensed are in for-profit arrangements; so, there’s financial pressures pushing in both directions.
Given the relative safety and expense, though, if controlled studies even find a small benefit, it would be worthwhile. And if they don’t, the vitamin C question can be put to rest once and for all, but in cancer treatment, we don’t have the luxury of jettisoning possibly effective relatively nontoxic treatments. We should revisit promising avenues, without prejudice, and with open minds.
To see any graphs, charts, graphics, images, and quotes to which Dr. Greger may be referring, watch the above video. This is just an approximation of the audio contributed by Katie Schloer.
Please consider volunteering to help out on the site.
- L J Hoffer, M Levine, S Assouline, D Melnychuk, S J Padayatty, K Rosadiuk, C Rousseau, L Robitaille, W H Miller Jr. Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. Ann Oncol. 2008 Nov;19(11):1969-74.
- H D Riordan, J J Casciari, M J González, N H Riordan, J R Miranda-Massari, P Taylor, J A Jackson. A pilot clinical study of continuous intravenous ascorbate in terminal cancer patients. P R Health Sci J. 2005 Dec;24(4):269-76.
- C M Stephenson, R D Levin, T Spector, C G Lis. Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer. Cancer Chemother Pharmacol. 2013 Jul;72(1):139-46.
- D A Monti, E Mitchell, A J Bazzan, S Littman, G Zabrecky, C J Yeo, M V Pillai, A B Newberg, S Deshmukh, M Levine. Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. PLoS One. 2012;7(1):e29794.
- F Cabanillas. Vitamin C and cancer: what can we conclude--1,609 patients and 33 years later? P R Health Sci J. 2010 Sep;29(3):215-7.
- C G Moertel, T R Fleming, E T Creagan, J Rubin, M J O'Connell, M M Ames. High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. N Engl J Med. 1985 Jan 17;312(3):137-41.
- C Jacobs, B Hutton, T Ng, R Shorr, M Clemons. Is there a role for oral or intravenous ascorbate (vitamin C) in treating patients with cancer? A systematic review. Oncologist. 2015 Feb;20(2):210-23.
- L N Cossey, F Rahim, C P Larsen. Oxalate nephropathy and intravenous vitamin C. Am J Kidney Dis. 2013 Jun;61(6):1032-5.
- S Ohno, Y Ohno, N Suzuki, G Soma, M Inoue. High-dose vitamin C (ascorbic acid) therapy in the treatment of patients with advanced cancer. Anticancer Res. 2009 Mar;29(3):809-15.
- S J Padayatty, H D Riordan, S M Hewitt, A Katz, L J Hoffer, M Levine. Intravenously administered vitamin C as cancer therapy: three cases.CMAJ. 2006 Mar 28;174(7):937-42.
- M Levine, S J Padayatty, M G Espey. Vitamin C: a concentration-function approach yields pharmacology and therapeutic discoveries. Adv Nutr. 2011 Mar;2(2):78-88.
- L J Hoffer, L Robitaille, R Zakarian, D Melnychuk, P Kavan, J Agulnik, V Cohen, D Small, W H Miller Jr. High-dose intravenous vitamin C combined with cytotoxic chemotherapy in patients with advanced cancer: a phase I-II clinical trial. PLoS One. 2015 Apr 7;10(4):e0120228.
- M K Wilson, B C Baguley, C Wall, M B Jameson, M P Findlay. Review of high-dose intravenous vitamin C as an anticancer agent. Asia Pac J Clin Oncol. 2014 Mar;10(1):22-37.
- G Morgan, R Ward, M Barton. The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies. Clin Oncol (R Coll Radiol). 2004 Dec;16(8):549-60.
- S Assouline, W H Miller. High-dose vitamin C therapy: renewed hope or false promise? CMAJ. 2006 Mar 28;174(7):956-7.
- S Mailankody, V Prasad. Comparative effectiveness questions in oncology. N Engl J Med. 2014 Apr 17;370(16):1478-81.
- S J Padayatty, A Y Sun, Q Chen, M G Espey, J Drisko, M Levine. Vitamin C: intravenous use by complementary and alternative medicine practitioners and adverse effects. PLoS One. 2010 Jul 7;5(7):e11414.
- J Blanchard, T N Tozer, M Rowland. Pharmacokinetic perspectives on megadoses of ascorbic acid. Am J Clin Nutr. 1997 Nov;66(5):1165-71.
Images thanks to Wendy via Flickr.
Republishing "The Role of Vitamin C in the Treatment of Terminal Cancer"
You may republish this material online or in print under our Creative Commons licence. You must attribute the article to NutritionFacts.org with a link back to our website in your republication.
If any changes are made to the original text or video, you must indicate, reasonably, what has changed about the article or video.
You may not use our material for commercial purposes.
You may not apply legal terms or technological measures that restrict others from doing anything permitted here.
If you have any questions, please Contact Us
The Role of Vitamin C in the Treatment of Terminal Cancer
LicenseCreative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)
Content URLDoctor's Note
If you missed the first two videos in this series, for the complete saga, see Intravenous Vitamin C for Terminal Cancer Patients and Vitamin C Supplements for Terminal Cancer Patients.
I discuss the conundrum of what do to about funding research of non-patentable natural treatments in Plants as Intellectual Property: Patently Wrong? On one hand, we want therapies to be accessible, but if no one profits off of it, who’s going to fund the necessary research?
Additional videos of interest include:
- Citrus Peels and Cancer: Zest for Life?
- What Is the Optimal Vitamin C Intake?
- Do Vitamin D Supplements Reduce the Risk of Dying from Cancer?
- Cranberries vs. Cancer
- Phytates for the Treatment of Cancer
- Food Antioxidants and Cancer
- Which Dietary Factors Affect Breast Cancer Most?
If you haven't yet, you can subscribe to our free newsletter. With your subscription, you'll also get notifications for just-released blogs and videos. Check out our information page about our translated resources.